Toremifene
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Toremifene: From Breast Cancer to HIV Infectious Disease
One-Sentence Summary
Toremifene is a selective estrogen receptor modulator (SERM), and while its established clinical use is in breast cancer, this data pack does not confirm its original approved indication in the current market. The TxGNN model predicts a possible link to HIV Infectious Disease, but this is supported by only 1 in vitro mechanistic publication with no clinical trials, and the mechanistic connection is indirect (antifungal activity against an HIV-associated opportunistic infection, not antiviral activity).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no license data in this pack) |
| Predicted New Indication | HIV Infectious Disease |
| TxGNN Prediction Score | 99.41% |
| Evidence Level | L5 |
| US Market Status | 未上市 (Not Marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, toremifene is a selective estrogen receptor modulator (SERM) structurally and pharmacologically related to tamoxifen, historically used in hormone receptor-related oncology settings.
The single supporting publication does not describe a direct drug–virus interaction. Instead, it reports that estrogen receptor antagonists like tamoxifen and toremifene bind fungal EF-hand proteins and exhibit fungicidal, anti-cryptococcal activity, synergizing with fluconazole and amphotericin B in vitro. Cryptococcal meningitis is a well-known opportunistic infection in HIV/AIDS patients — so the biological rationale here is indirect: potential utility as adjunctive antifungal therapy in HIV-associated cryptococcosis, not as an HIV/antiretroviral agent.
The high TxGNN score (0.994) most likely reflects the knowledge graph’s encoding of “opportunistic infection comorbidity” links between toremifene’s antifungal target space and HIV disease nodes, rather than a validated drug-disease mechanistic pathway. Without MOA data, safety data, or any clinical trial evidence, this connection should be treated as a hypothesis-generating signal only.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 24520056 | 2014 | In vitro mechanistic study | mBio | Estrogen receptor antagonists tamoxifen and toremifene show fungicidal, anti-cryptococcal activity by binding fungal EF-hand proteins; synergize with fluconazole and amphotericin B in vitro — relevant to HIV-associated cryptococcal infection, not direct antiviral activity |
US Market Information
No licensing/authorization records available in this data pack (market status: 未上市 / Not Marketed, 0 total licenses).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence level is L5 (model prediction only) — the sole supporting publication demonstrates an indirect antifungal mechanism relevant to an HIV-associated opportunistic infection, not a direct anti-HIV mechanism, and the drug is not currently marketed in this jurisdiction.
To proceed, the following is needed:
- Toremifene’s confirmed original indication and MOA data (currently a Blocking/High severity data gap)
- TFDA package insert warnings, contraindications, and safety data (Blocking data gap — required before any S1 safety evaluation)
- Additional preclinical or clinical evidence directly linking toremifene to HIV pathophysiology (not just opportunistic co-infection)
- Clarification of whether the intended indication is HIV itself or HIV-associated cryptococcal meningitis, as these require different evidence pathways
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.